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a b s t r a c t
Elevated total cholesterol in midlife has been associated with increased risk of dementia in later life.
We have previously shown that low-density lipoprotein (LDL) is more oxidized in the plasma of
dementia patients, although total cholesterol levels are not different from those of age-matched controls.
β-Amyloid (Aβ) peptide, which accumulates in Alzheimer disease (AD), arises from the initial cleavage of
amyloid precursor protein by β-secretase-1 (BACE1). BACE1 activity is regulated by membrane lipids and
raft formation. Given the evidence for altered lipid metabolism in AD, we have investigated a mechanism
for enhanced Aβ production by SH-SY5Y neuronal-like cells exposed to oxidized LDL (oxLDL). The
viability of SH-SY5Y cells exposed to 4 μg oxLDL and 25 mM 27-hydroxycholesterol (27OH-C) was
decreased signiﬁcantly. Lipids, but not proteins, extracted from oxLDL were more cytotoxic than oxLDL.
In parallel, the ratio of reduced glutathione (GSH) to oxidized glutathione was decreased at sublethal
concentrations of lipids extracted from native and oxLDL. GSH loss was associated with an increase in
acid sphingomyelinase (ASMase) activity and lipid raft formation, which could be inhibited by the
ASMase inhibitor desipramine. 27OH-C and total lipids from LDL and oxLDL independently increased
Aβ production by SH-SY5Y cells, and Aβ accumulation could be inhibited by desipramine and by
N-acetylcysteine. These data suggest a mechanism whereby oxLDL lipids and 27OH-C can drive
Aβ production by GSH depletion, ASMase-driven membrane remodeling, and BACE1 activation in
neuronal cells.
& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Alzheimer's disease (AD)1 is the most common neurodegenerative
disease and is characterized by progressive decline in cognitive
performance with loss of memory, orientation, and judgment [1]. Loss
of synapses and cholinergic neurons, accumulation of extracellular
Aβ plaques, and intraneuronal neuroﬁbrillary tangles of hyperpho-
sphorylated tau are major hallmarks of the AD brain [1].
Aβ is derived from amyloid precursor protein (APP), an abun-
dant type I membrane protein that is a substrate for at least three
proteolytic (“secretase”) activities designated α, β, and γ. The
major proteolytic pathway, undergone by 95% of the APP in
neurons, is α–γ, i.e., APP is ﬁrst cleaved by an α-secretase within
the Aβ region and subsequently by the γ-secretase. The second
proteolytic pathway, which leads to the formation of Aβ, is the β–γ
pathway. In this case, APP is ﬁrst cleaved by the β-secretase β-site
amyloid cleaving enzyme (BACE1), a membrane-spanning aspartic
protease, with further processing by the γ-secretase to produce
the 4-kDa Aβ peptide [2]; the initial cleavage of APP by BACE1 is
the rate-limiting step for Aβ production in AD brains.
Lipids are key regulators of brain function and have been
increasingly implicated in neurodegenerative disorders, including
AD; a major risk factor for late-onset AD is the ε4 allelic variant of
ApoE, which encodes a protein involved in cholesterol metabolism
and lipid transport [3]. Importantly, a variety of genes have been
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recently linked to late-onset AD through genome-wide association
studies and are directly or indirectly connected to lipid metabo-
lism or cellular membrane dynamics [4,5].
In support of a role for lipids in AD, Chan et al. [6] analyzed the
prefrontal cortex, entorhinal cortex, and cerebellum of late-onset
AD patients and found an elevation of diacylglycerol and sphingo-
lipids in the prefrontal cortex of AD patients. Enrichment of
lysobisphosphatidic acid, sphingomyelin, the ganglioside GM3,
and cholesterol esters was observed in the affected entorhinal
cortex but no change in lipids occurred within the cerebellum.
Most recently, a ﬁngerprint of 10 plasma lipids that deﬁnes AD
presence has been identiﬁed in older adults [7]; however, it is
unknown whether they play a mechanistic role in disease devel-
opment or progression.
Membrane lipids are involved in the trafﬁcking and/or activity
of the key membrane-bound proteins controlling Aβ levels,
including APP, BACE1, and presenilins; ﬁrst, the regulation of
BACE1 activity is determined by its access to APP, which is in turn
lipid-dependent and involves lipid raft formation; three groups of
lipids that stimulate proteolytic activity of BACE are (1) neutral
glycosphingolipids (cerebrosides), (2) anionic glycerophospholi-
pids, and (3) cholesterol [8]; second, γ-secretase activity is
regulated by membrane levels of cholesterol and sphingomyelin
(SM) [9]. The enzymes most strongly implicated in regulation of
these lipids are HMG-CoA reductase and sphingomyelinase. Third,
lipids such as ganglioside GM1 modulate the pathogenic potential
of Aβ by affecting its propensity to aggregate [10]. Cholesterol is
highly enriched in the brain and is a major constituent of normal
neuronal membranes. Whereas brain cholesterol homeostasis is
regulated through de novo synthesis and is normally segregated
from peripheral circulation owing to the impermeability of the
blood–brain barrier (BBB) [11,12], oxysterols such as 27-hydro-
xycholesterol (27OH-C) are known to cross the blood–brain barrier
more readily than cholesterol [13,14]. Moreover, 27OH-C has been
shown to accumulate in AD brains [15] and aberrant lipid home-
ostasis is implicated in AD [16]. In contrast, the related 24OH-C is
produced within the brain and is found at raised levels in plasma
from AD patients
Not only cholesterol is transported by lipoproteins; for exam-
ple, SMs are transported by low-density lipoproteins (LDL) [17]
and high-density lipoproteins carry carotenoids and ApoA1, and
lower concentrations of either are independent risk factors for AD
[18,19]. We have previously shown in a population of older adults
that oxidized LDL is increased in AD patients with vascular risk
factors compared to age-matched control subjects [11]. Levels of
protein carbonyls on LDL were associated with cognitive impair-
ment, although total cholesterol levels were not different from
those of age-matched controls [11].
Exposure of a variety of cells to oxLDL can trigger intracellular
oxidative stress and glutathione (GSH) depletion [20]. GSH is
consumed in the detoxiﬁcation of lipid peroxidation products,
catalyzed by GSH peroxidase. According to the extent of lipid
peroxide burden, GSH loss is usually transient and after several
hours is restored through de novo synthesis. Lipid raft formation is
also accelerated during oxidative stress, as the activity of sphin-
gomyelinase, an enzyme responsible for cleaving membrane
sphingolipids, is increased by GSH depletion [21]. This illustrates
a relationship between extracellular lipoprotein oxidation, intra-
cellular redox imbalance, and membrane remodeling, although the
nature of the molecules in oxLDL that mediate this effect is
unknown.
Others have shown recently that 27OH-C increases BACE1
levels in hippocampal organotypic slices from adult rabbits [22]
and in human SH-SY5Y neuroblastoma cells [23]. These studies
have also demonstrated that Gadd153 and nuclear factor-κB
regulate BACE1 expression in a concerted fashion in response to
27OH-C [24]. These studies provide evidence that BACE1 expres-
sion is important for Aβ formation; however, they do not examine
the effect of 27OH-C on the pathway, e.g., in membrane reorgani-
zation that is required for BACE1 activation, nor has the (patho)
physiological source of 27OH-C been investigated.
Recognizing the association of systemic hypercholesterolemia in
midlife with AD in later life, we have therefore investigated the
hypothesis that systemically oxidized 27OH-C and oxidized lipids in
general derived from oxLDL in plasma deplete GSH in neuronal cells,
promote lipid raft formation through enhanced sphingomyelinase
activity, and increase Aβ formation. Our approach to identifying
novel pathways for reducing toxic Aβ formation through improved
understanding of 27OH-C effects and production upstream of Aβ is
an important strategy in the search for new therapeutic targets.
Materials and methods
Cell culture
The neuroblastoma cell line SH-SY5Y from the American Type
Culture Collection was maintained in RPMI 1640 medium (Gibco)
containing 10% fetal bovine serum, 1% nonessential amino acids,
and 200 U/ml penicillin and streptomycin at 37 1C in a humidiﬁed
atmosphere of 5% CO2 and 95% air. All reagents were from Sigma
unless otherwise stated.
Isolation, modiﬁcation, and characterization of LDL
Blood for lipoprotein isolation was drawn from the antecubital
vein of normolipemic healthy volunteers into EDTA after 12 h of
fasting. Control subject LDL for in vitro oxidation and analysis
was from healthy controls recruited at Aston University who
showed no evidence of cognitive impairment. Ethical approval
was obtained from the Aston University ethics committee. None of
the volunteers were taking antioxidant supplements.
AD subjects were recruited from the Unit of Cognitive Frailty,
Neurology Outpatient Clinic, Cologne, Germany, after diagnosis of
AD using NINCDS–ADRDA criteria [7]. Informed consent was
obtained from the patients or their caregivers according to severity
of disease by the local ethics committee.
LDL was isolated from plasma by density-gradient ultracentri-
fugation with potassium bromide (KBr) as previously described
[25,26]. To remove residual KBr and EDTA before starting the
in vitro oxidation reaction, the LDL was passed through a PD-10
column (GE Healthcare, Little Chalfont, UK). OxLDL was prepared
by incubating with 10 mM CuSO4 for 1 h at 37 1C and then the
reaction was stopped by adding 10 1mM EDTA as previously
described [26]. Copper and EDTA were then removed by passing
the samples through PD-10 columns (GE Healthcare) against
phosphate-buffered saline (PBS). To sterilize and remove aggre-
gates, both LDL and oxLDL were ﬁltered through a 0.22-mm ﬁlter
(Millipore), stored under nitrogen in the dark at 4 1C, and used
within 2 weeks of preparation. To ensure the LDL did not undergo
further oxidation, the MDA concentration was measured as thio-
barbituric acid-reactive substances. MDA concentration was not
affected signiﬁcantly (2.570.1 versus 2.670.08 nmol MDA/mg
for LDL and 3.8 versus 3.970.6 nmol MDA/mg for oxLDL)
after storage. The ﬁnal protein concentration was determined by
bicinchoninic acid assay (BCA assay) against a bovine serum
albumin standard and the amounts of LDL used in experiments
are described by protein content. The purity and charge of LDL and
oxLDL were evaluated by examination of electrophoretic migration
in a 1% agarose gel. 8-Isoprostane F2α levels in LDL and oxLDL
were measured by ELISA (Cayman Chemicals, Ann Arbor, MI, USA).
I.H.K. Dias et al. / Free Radical Biology and Medicine 75 (2014) 48–59 49
Extraction of lipids and proteins from LDL
LDL lipids (LDL-L) were extracted from LDL using the Folch
method by addition of 160 μl of ice-cold methanol (containing
50 μg/ml BHT) followed by the addition of 320 μl of ice-cold
chloroform and incubation for 20 min on ice with occasional
vortex mixing. High-purity water (150 μl) was added and the
sample kept on ice for an additional 10 min with occasional
mixing. The sample was centrifuged for 5 min at 2000g and the
upper (aqueous) phase was removed and reextracted by addition
of 250 μl of ice-cold chloroform:methanol (2:1, v/v) as above. The
upper phase was discarded and both organic phases were com-
bined, dried under nitrogen gas, and kept at 80 1C until further
use. Extracted lipids for cell culture experiments were conjugated
to fatty acid-free bovine serum albumin (BSA) in serum-free RPMI
1640 [25].
Cell culture treatments
SH-SY5Y cells (5105/ml) were incubated overnight at 37 1C
in a humidiﬁed atmosphere. Cells received RPMI medium replace-
ment before 2 h of each treatment. Cells were treated with
0.8–8 mg/ml LDL-L or oxLDL-L or 2.5–25 mM 27OH-C for 2 or
16 h. SH-SY5Y cells were cotreated with 10 mM desipramine or
3 mM N-acetylcysteine (NAC) for 2 or 16 h. To measure secretory
forms of Aβ, the medium was removed from SH-SY5Y cells and
replaced with 2 ml of reduced-serum medium (Opti-MEM). Cells
were treated with 4 mg/ml LDL, 4 mg/ml oxLDL, or an equal volume
of medium for 16 h. Supernatants were transferred into a micro-
centrifuge tube and centrifuged to remove any dead cells, then the
clear supernatant was transferred into a new microcentrifuge tube
and vacuum concentrated down to 100 ml.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay
Four hours before the completion of each experiment, SH-SY5Y
cells were incubated with MTT solution (1 mg/ml) at 37 1C and
analyzed for metabolic activity compared to untreated controls [18].
Measurement of intracellular GSH and oxidized glutathione (GSSG)
After 2 or 16 h of incubation, 27OH-C, LDL, oxLDL, extracted-
lipid-treated, and untreated control SH-SY5Y (5105) cells were
centrifuged and washed twice with PBS. Sulfosalicylic acid (3.33 ml
of 100% in distilled water) was then added to the cell pellet and
GSH and GSSG levels were assessed by the GSH recycling assay as
described by Qin et al. [27]. Protein concentration was measured
using the BCA assay.
Acid sphingomyelinase (ASMase) activity assay
ASMase activity in SH-SY5Y cells was measured as described
previously with some modiﬁcations [21]. Control and treated SH-
SY5Y cells (1107) were centrifuged and washed with ice-cold
PBS to remove the medium. The cell pellet was resuspended in
1 ml of lysis buffer (25 mM Tris–HCl buffer (pH 5), 2 mM EDTA,
2 mM EGTA, 1 mM phenylmethylsulfonyl ﬂuoride, 20 mg/ml E-64).
Cell extracts were homogenized by passing ﬁve times through a
25-gauge needle and used as the enzyme source.
The assay buffer (200 ml) consisted of 15 mM 2-N-hexadecanoy-
lamino-4-nitrophenylphosphorylcholine (Calbiochem, San Diego,
CA, USA), 100 mM Tris–HCl buffer (pH 5), 10 mM MgCl2, and 10 ml
of the cell extract. Incubation followed at 37 1C for 60 min; the
enzyme reaction was terminated by adding 400 ml of 100 mM
glycine buffer (pH 10.5) and 700 ml of ethanol. The suspension
was vortexed and centrifuged at 2000g for 10 min. The absorbance
of the supernatant solution was measured spectrophotometrically
at 410 nm.
Isolation of lipid raft microdomains by gradient centrifugation
Lipid rafts were isolated as previously described [28]. SH-SY5Y
cells (1107 cells) were lysed in 1 ml of MNE buffer (150 mM
NaCl, 2 mM EDTA, 25 mM 2-(N-morpholino)ethanesulfonic acid,
with 1% protease inhibitor cocktail, pH 6.5) containing 1% Triton X-
100 on ice for 30 min. Cell extracts were homogenized by ﬁve
passages through a 21-gauge needle. Lysates were obtained by
centrifuging at 14,000g, 4 1C, for 5 min to remove the nuclei and
insoluble materials. The cell lysates (1 ml) were mixed 1:1 with
85% sucrose solution, layered in the bottom of the centrifuge tube
(Ultra Clear Beckman centrifuge tubes), and overlaid sequentially
with 6 ml of 30% and 3.5 ml of 5% sucrose solution to make a
noncontinuous sucrose gradient. Samples were centrifuged at
20,000g for 16 h at 4 1C using an SW41Ti rotor (Beckman).
Fractions (1 ml) numbered 1–9 were collected from the top of
the tube downward and proteins in each fraction were precipi-
tated with 5% trichloroacetic acid for 30 min on ice.
Proteins in lipid raft fractions were isolated by centrifugation at
13,000g, 4 1C, for 15 min. The protein pellet was carefully washed
with cold acetone twice, air dried, and then resuspended in
modiﬁed Laemmli buffer (4 M urea, 0.2% ABF-14, 20% dimethyl
sulfoxide, 4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004%
bromophenol blue, and 0.125M Tris–HCl, pH 6.8). Samples were
heated 5 min at 95 1C before storage at 20 1C for later analysis by
Western blot.
Western blot for analysis of lipid rafts
For immunodetection of lipid-raft-associated proteins, 15 μl of
each fraction in modiﬁed Laemmli buffer was subjected to 10%
SDS–PAGE, transferred onto a PVDF membrane, and blocked with
3% BSA. The membrane was probed with the primary monoclonal
antibody anti-ﬂotillin-1 (1:1000, BD Biosciences) for 2 h at room
temperature followed by extensive washing and then incubation
with horseradish peroxidase-labeled anti-rabbit IgG (1:5000)
for 2 h. The immunoreactive bands were detected by enhanced
chemiluminescence methods (GE Healthcare).
Confocal imaging
To stain lipid rafts, SH-SY5Y cells were rinsed with chilled
growth medium and then incubated with 1 μg/ml cholera toxin B
(CTB)–Alexa Fluor 488 at 4 1C for 15 min before ﬁxation in 4%
paraformaldehyde. CTB binds to lipid rafts with some limited
speciﬁcity toward ganglioside GM1 [29]. Coverslips were mounted
in Anti-Fade DAPI-Fluoromount-G (SouthernBiotech, Birmingham,
AL, USA) and viewed using a Leica confocal microscope (Leica
Microsystems, Wetzlar, Germany).
β-Amyloid ELISA
A sandwich ELISA was performed to detect secreted β-amyloid
levels. The ELISA plate was incubated at 4 1C overnight with
β-amyloid, 1-16 (6E10) monoclonal antibody (Covance Research
Products, Denver, PA, USA), followed by washing with PBST. BSA
(3%) in PBS was used to block for 1 h and then washed with PBST.
A standard curve from 0 to 2.5 nmol/L of β-amyloid protein
standard was prepared. Samples of LDL, oxLDL, and their respec-
tive lipid- and control-treated culture media were adjusted to
20 mg/ml protein in carbonate buffer and incubated for 2 h. Anti-β-
amyloid antibody was added and incubated for 1 h, followed by
washing with PBST and incubation with anti-rabbit peroxidase
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conjugate antibody for 30 min. After a thorough washing with
PBST, citrate buffer (with hydrogen peroxide and o-phenylenedia-
mine) was added with detection at 490 nm.
Electrospray ionization mass spectrometry (ESI–MS)
Oxidized cholesteryl esters were identiﬁed by scanning for
precursors of m/z 369. Extracted lipid samples were initially
dissolved in a small volume of chloroform:methanol (1:1, v/v)
and then diluted 10 times into 200 ml of 0.1 mM ammonium
acetate in methanol. Samples were analyzed by ESI in positive-
ion mode on a QTrap5500 instrument (ABSciex, Warrington, UK)
by direct infusion at a ﬂow rate of 5 μl/min. The spray capillary
voltage was set at 5500 V and declustering potential at 50 V, with
a curtain gas setting of 20 and a source temperature of 150 1C. For
the precursor ion scans the precursor of m/z 369.0 Da was selected
with unit resolution in both quadrupoles, a collision energy of
30 V, and an m/z range of 200–1000 at 5 s/scan with a 0.1-Da step
size. For each spectrum 100–500 scans were averaged. Further
conﬁrmation of the occurrence of lipid oxidation in oxLDL com-
pared to the control LDL was undertaken by analysis of phospho-
lipids in the positive-ion ESI mode. Phosphatidylcholines (PCs)
were identiﬁed by scanning for precursors of the phosphocholine
fragment ion at m/z 184 as described above for cholesterol with
the following changes: precursor of m/z 184.1, collision energy
47 V, declustering potential 65 V, mass range m/z 300–1000 Da,
and scan time 7 s. Oxidized PCs were identiﬁed from their mono-
isotopic mass.
Data analysis
Data were analyzed using GraphPad Prism software (version 5).
Unless speciﬁed all data are presented as the mean 7 SEM of at
least three independent experiments, each performed in triplicate.
Statistical analysis was performed using analysis of variance
followed by Tukey's multiple comparison test.
Results
27OH-C decreases SH-SY5Y GSH/GSSG ratio and increases Aβ
secretion
To understand the effects of oxidized molecules on neuronal
cells, we sought to establish concentrations of 27OH-C that
Fig. 1. Effects of 27OH-C on SH-SY5Y cell viability, GSH level, and Aβ secretion. (A) SH-SY5Y cells were challenged with 2.5–25 μM 27OH-C for 16 h and cell viability was
measured by MTT assay. (B) SH-SY5Y cells (2104) were challenged with 10 μM 27OH-C for 16 h in the presence or absence of 3 mM NAC. (C) Intracellular GSH and GSSG
levels were measured, after treating cells with 2.5–10 mM 27OH-C for 2 h, by the GSH recycling assay and the GSH/GSSG ratio is shown. (D) Protein levels were measured by
BCA assay. Results are from three independent experiments. Signiﬁcant differences were calculated using one-way ANOVA followed by Tukey's multiple comparison test,
where *P o 0.05, **P o 0.01, and ***P o 0.001.
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induced stress but were not toxic over 16 h (Fig. 1A). After 16 h,
25 mM 27OH-C caused a signiﬁcant loss of viability, which could be
prevented by co-incubation with a thiol donor, NAC (Fig. 1B). Using
nontoxic concentrations of 27OH-C at 16 h (10 mM), we observed a
dose-dependent decline of the GSH/GSSG ratio up to 50% without
effect on viability (Fig. 1C). This was largely due to loss of GSH
while GSSG remained unchanged, and the decrease in GSH/GSSG
was inhibited by 3 mM NAC (data not shown). Consistent with
previously reported ﬁndings, we also observed an increase in
Aβ secretion from SH-SY5Y cells over 16 h in the presence of a
nontoxic concentration of 27OH-C and this effect was prevented
by both NAC and the acid sphingomyelinase inhibitor desipramine
(Fig. 1D).
OxLDL induces a decrease in SH-SY5Y cell viability that
is lipid-dependent
To simulate minimally modiﬁed LDL found in the plasma of
patients with hypercholesterolemia and dementia, native LDL
was incubated with 10 μM CuSO4 for 1 h. This increased the
Fig. 2. SH-SY5Y viability after lipid treatments. (A) Plasma LDL (200 μg/ml) was incubated at 37 1C for 1 h in the presence of CuSO4 (10 μM). (B) LDL was isolated from age-
and sex-matched AD patients and control plasma (n ¼ 3). Electrophoretic mobility of LDL was measured on an agarose gel. (C and D) SH-SY5Y cells were challenged with
0.8–8 μg of LDL, oxLDL, or their extracted lipids (-L) for (C) 2 or (D) 16 h. Data variance was less than 5%. (E) SH-SY5Y cells were treated with 8 mg of LDL-L or oxLDL-L in the
presence of 3 mM NAC (mean 7 SEM). Cell viability was measured by the MTT assay. Results are from three independent experiments. Signiﬁcant differences were
calculated using one-way ANOVA followed by Tukey's multiple comparison test, where *P o 0.05, **P o 0.01, and ***P o 0.001.
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electrophoretic mobility on agarose gel (Rf: 0.4970.04) compared
to untreated LDL (Rf: 0.3870.05; Fig. 2A), suggesting the loss of
positive charge on basic amino acids, e.g., lysine residues, due to
conjugation with MDA. This observation was consistent with the
electrophoretic mobility on agarose gel (Rf: 0.5170.12; Fig. 2B) of
LDL isolated from Alzheimer disease patients (Table 1) compared
to age- and sex-matched healthy controls (Rf: 0.470.11). The
degree of lipid oxidation of LDL and oxLDL was determined as
8-isoprostane F2α levels (15.571 pg/mg of LDL and 2672.5
pg/mg of oxLDL). The occurrence of phospholipid oxidation in
oxLDL was supported by MS/MS analysis, which showed the
presence of chain-shortened oxidized products (Supplementary
Fig. 1) in agreement with the literature [30]. Cell viability was not
affected by any LDL, oxLDL, or lipid treatment within 2 h (Fig. 2C).
At 16 h, the viability of LDL-treated SH-SY5Y cells was not
signiﬁcantly decreased at any concentration tested (Fig. 2D) and
oxLDL-extracted protein did not have any effect on viability either
(data not shown). In contrast, 8 μg oxLDL decreased the cell
viability signiﬁcantly by 34% (P o 0.05) and lipids extracted from
oxLDL resulted in 45% cell loss (Fig. 2D; P o 0.01); toxicity could
be prevented by co-incubation with 3 mM NAC (Fig. 2E).
LDL, oxLDL, and their lipids deplete intracellular GSH level
and GSH/GSSG ratio in SH-SY5Y cells
We investigated whether intracellular GSH concentration was
affected by nontoxic concentrations of LDL and oxLDL and their
lipids; Fig. 3A conﬁrms that despite the lack of toxicity, after 2 h
treatment with 4 μg/ml LDL, GSH was signiﬁcantly decreased (P o
0.05). Furthermore, lower concentrations (1.6 and 4 μg/ml) of
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Fig. 3. LDL, oxLDL, and their extracted lipids decrease the GSH/GSSG ratio in SH-SY5Y cells. SH-SY5Y cells were treated with 0.8, 1.6, or 4 μg of LDL, oxLDL, or their lipids (-L)
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from three independent experiments and show the mean 7 SEM. Signiﬁcant differences were calculated using one-way ANOVA followed by Tukey's multiple comparison
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Table 1
Demographics of patient populations.
Controls (n ¼ 10) AD (n ¼ 10)
Age (years) 7170.3 81.671.4
BMI (kg/m2) 23.770.34 24.170.69
Total cholesterol (mmol/L) 5.6770.17 5.2470.32
LDL cholesterol (mg/dl) 121.577.6 113.2711.1
I.H.K. Dias et al. / Free Radical Biology and Medicine 75 (2014) 48–59 53
oxLDL decreased intracellular GSH concentration to a greater
extent (P o 0.01 and P o 0.001, respectively).
Lipids isolated from LDL effectively depleted intracellular GSH
levels at much lower concentrations than for intact LDL: 0.8 μg/ml
LDL-L, 9.470.59 nmol GSH/mg of protein, P o 0.05; 1.6 μg/ml
LDL-L, 7.1370.11 nmol GSH/mg of protein, P o 0.001; and 4 μg/ml
LDL-L, 5.2270.26 nmol GSH/mg of protein, P o 0.001. Greater GSH
depletion was observed with lipids isolated from oxLDL compared
to those isolated from native LDL (Fig. 3A). Intracellular GSSG
concentrations were not different between control and treatments
(Fig. 3B). Nevertheless, the ratio of reduced to oxidized GSH was
signiﬁcantly decreased (Fig. 3C) after LDL, oxLDL, and lipid treat-
ments. Co-incubation with NAC was sufﬁcient to prevent the
alteration in reduced to oxidized GSH observed in SH-SY5Y cells
after treatment with LDL and oxLDL lipids (Fig. 3D).
27OH-C, LDL, oxLDL, and their lipids increase acid sphingomyelinase
activity
To explore whether 27OH-C or LDL could modulate ASMase
activity, SH-SY5Y cells were treated with 27OH-C, LDL, oxLDL, or
lipids extracted from LDL and oxLDL. After 2 h of treatment
(Fig. 4A) ASMase activity was signiﬁcantly increased under all
the conditions tested (2.970.31, 2.170.14, 2.970.15, 2.870.16,
3.370.11 U/mg protein) compared to untreated cells (1.470.1 U/mg
protein). After 16 h treatment (Fig. 4B), ASMase activity was
increased signiﬁcantly (5.070.02, 5.3270.35 U/mg protein, P o
0.05; 5.2170.6 U/mg protein, P o 0.05; and 5.5870.44 U/mg
protein, P o 0.01, respectively) compared to the control cells
(2.9670.34 U/mg protein).
Further conﬁrmation that GSH depletion was involved in the
activation of ASMase was established by using buthionine sulfox-
imine (BSO). BSO, an inhibitor of γ-glutamylcysteinyl ligase, the
rate-limiting enzyme for GSH synthesis and an effective agent for
depleting intracellular GSH, caused an increase in ASMase activity.
Desipramine (10 mM) signiﬁcantly decreased the ASMase activity
in both control (0.6970.1 U/mg protein) and BSO-treated cells
(0.9670.07 U/mg protein; P o 0.05).
OxLDL lipids increase lipid raft formation
To determine the effect of intracellular redox status on the
redistribution of membrane lipids, lipid rafts were labeled with
cholera toxin subunit B, which also detects glycosylphosphatidy-
linositol (GPI)-anchored proteins and GM1 ganglioside [29]
(Fig. 5A–H). Raft formation was promoted by oxidized lipids after
2 h but there was no signiﬁcant raft presence at 16 h (data not
shown).
SH-SYSY cell membranes were analyzed for detergent-
insoluble regions by sucrose density gradient ultracentrifugation
and stained for the raft marker ﬂotillin. Lipids isolated from
SH-SY5Y cells treated with minimally oxidized LDL, 27OH-C, and
BSO increased lipid raft domains at 2 h. Desipramine inhibited lipid
raft formation. Treatment of SH-SY5Y cells with LDL, oxLDL, their
lipids (4 mg of LDL protein), and oxidized cholesterol (10 mM 27OH-
C) promoted the redistribution of ﬂotillin, a lipid raft marker, to
the major raft fraction 3 (Fig. 5I). There was no signiﬁcant raft
presence after 16 h (data not shown).
BACE1 activity and β-amyloid production in SH-SY5Y is increased by
LDL and GSH depletion
The regulation of BACE1 and its access to APP is lipid depen-
dent and involves lipid rafts [8]; therefore, we explored whether
BACE1 activity was increased by oxLDL and native LDL and their
lipids. Fig. 6A conﬁrms that after 2 h treatment with 27OH-C, BSO,
LDL, oxLDL, or their lipids the activity of BACE1 was signiﬁcantly
increased (16077.2, 161.679.0, 146.375.5, 209.779.4, 134.57
5.7, 203.9712.04 U) compared to untreated cells (64.1278.2 U).
This effect could be mimicked by depletion of GSH using BSO.
However, by 16 h the increases in BACE1 activity by treatments
were less than those observed at 2 h and not signiﬁcantly
increased by any of the treatments (Fig. 6B).
Given the early increase in BACE1 activity within SH-SY5Y cells
exposed to 27OH-C, LDL, and oxLDL, we explored whether APP and
Aβ levels were also modulated under these conditions. Fig. 6C
conﬁrms that Aβ release is increased by oxLDL lipids. 27OH-C
mimicked the effects of oxLDL on the release of Aβ.
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Fig. 4. Effects of 27OH-C, LDL, oxLDL, and their lipids on ASMase activity. SH-SY5Y
cells were pretreated with LDL, oxLDL, or their lipids (4 μg of protein) for (A) 2 or
(B) 16 h. Pretreated or untreated cells were further incubated with 10 μM
desipramine, an inhibitor of acid sphingomyelinase, for 1 h before ASMase activity
was measured. Results are from three independent experiments (n ¼ 3). Signiﬁcant
differences were calculated using one-way ANOVA followed by Tukey's multiple
comparison test, where *P o 0.05 and #P o 0.01.
I.H.K. Dias et al. / Free Radical Biology and Medicine 75 (2014) 48–5954
Fig. 5. 27OH-C, BSO, LDL, oxLDL, and their lipids increase the distribution of ﬂotillin into lipid rafts of SH-SY5Y cells. SH-SY5Y cells were treated with (A) vehicle control,
(B) LDL, (C) oxLDL, (D) LDL-L, (E) oxLDL-L, (F) 27OH-C, (G) BSO, and (H) desipramine with oxLDL-L for 2 h, labeled for GPI-anchored proteins with cholera toxin B (green),
stained for nuclei with DAPI (blue), and analyzed by confocal microscopy. White arrows indicate strongly staining raft regions. (I) Cells treated with LDL, oxLDL, and their
lipids were extracted with 1% Triton X-100 lysis buffer and applied to discontinuous sucrose gradients. Proteins were extracted and the blot was analyzed for the lipid raft
marker protein ﬂotillin-1. Flotillin-1 distribution into lipid raft fraction 3 was expressed as a % of total ﬂotillin in all fractions. Signiﬁcant differences were calculated using
one-way ANOVA followed by Tukey's multiple comparison test, where ***P o 0.001. Images are representative of three independent experiments (n ¼ 3).
I.H.K. Dias et al. / Free Radical Biology and Medicine 75 (2014) 48–59 55
Comparison of LDL-L and oxLDL-L lipid proﬁles by MS
To investigate the presence of oxidized cholesterol in lipid
extracts from LDL and oxLDL, we used positive-ion electrospray
mass spectrometry with scanning for precursors of m/z 369 to
detect ions containing the cholesterol core. As shown in Fig. 7A
and B, we observed a dominant cholesterol ion at m/z 369
corresponding to the [MþHH2O]þ species, and the [MþNH4]þ
species at m/z 404 also gave a strong signal. A signal at m/z 666
could be consistent with the presence of cholesterol linoleate.
Oxidation of LDL resulted in the appearance of signals at m/z 544
and 558, corresponding to cholesterol esters with ω-oxidized
truncated acyl chains (C8 and C9, respectively). These products
have been detected previously in human vascular lesions [31].
Oxidation products of the cholesterol core do not produce the
diagnostic m/z 369 ion upon collision-induced dissociation (CID)
[31] and could not be observed using this method.
Discussion
Here, we have shown that oxidized lipid-driven membrane
remodeling, which requires glutathione depletion and sphingo-
myelinase activation, increases β-amyloid secretion from SH-SY5Y
cells through BACE1, supporting a unifying hypothesis for the
involvement of systemic LDL oxidation and neurodegeneration.
We have previously shown that LDL is more oxidized in the
plasma of dementia patients, although total cholesterol levels
remained unchanged [11]. Peripheral oxLDL is a likely source for
oxidized lipid accumulation in aging brains and the transport of
lipoproteins such as oxLDL into the brain is increased after the loss
of BBB integrity with aging [32]. Similarly, extravascular modiﬁed
LDL has been shown to cause injury through oxidative damage in
the retina, which is metabolically supported through blood–retinal
barrier [33]. There is strong evidence from cross-sectional and
observational studies for an association between elevated serum
cholesterol in midlife and later development of AD [34]. Recently,
a number of comorbidities have been associated with increased
risk of developing AD, including hypercholesterolemia and type
2 diabetes [12]; these conditions also associate with increased
systemically oxidized lipids and may be potential modiﬁable risk
factors for AD [1].
SH-SY5Y neuroblastoma cells are a subline of the parental line
SK-N-SH and are positive for tyrosine hydroxylase and dopamine-β-
hydroxylase, characteristic of catecholaminergic neurons [35]. SH-
SY5Y cells express APP and secretases [36], and previous studies
have shown oxysterol-mediated Aβ release in this system [23].
Lipid peroxides are detoxiﬁed intracellularly through the GSH/
glutathione peroxidase/glutathione reductase cycle, resulting in a
net consumption of GSH [37]. Of the LDL, oxLDL, and extracted
lipids studied here, oxLDL-lipid treatments exhibit the greatest
direct toxicity and early depletion of intracellular GSH in SH-SY5Y
cells. However, neuronal loss in AD is a consequence of the gradual
accumulation of toxic β-amyloid aggregates over decades rather a
consequence of acute stress; therefore we focused on nontoxic
concentrations of lipids to investigate oxLDL-lipid effects on
β-amyloid production. We also investigated 27OH-C, which is a
major oxysterol in oxLDL formed in the periphery, but which
crosses the blood–brain barrier when the barrier is dysfunctional.
This oxysterol has been reported previously to antagonize the protec-
tive effect of 24OH-C against generation of neurotoxic β-amyloid [23].
However, 24OH-C is also reported to promote the binding, uptake, and
toxicity of β-amyloid to neurons [38].
After LDL, oxLDL, or 27OH-C exposure, GSH depletion occurred
within 2 h in SH-SY5Y cells. GSH and its oxidized form GSSG are
major contributors to cellular redox balance [39]. Cellular GSH
homeostasis is dependent on the activity of glutamate–cysteine
ligase (GCL) and cysteine availability [40]; expression of the rate-
limiting enzyme GCL is coupled to cellular redox state through the
Nrf2–Keap1 system, providing a mechanism for cellular adaptation
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to oxidative stress through de novo GSH biosynthesis [40]. There-
fore, in healthy cells the loss of GSH after removal of lipid
peroxides should give rise to an increase in de novo GSH synthesis
with restoration of the cellular redox state. Indeed, when using
nontoxic concentrations of oxLDL, 27OH-C, and lipids, which
induced GSH loss, we observed that after 16 h the GSH was
restored to control levels, which is indicative of adaptation (data
not shown). GSSG concentrations were not altered signiﬁcantly
during treatments, probably owing to the efﬁcient export of
oxidized GSSG or its involvement in mixed-disulﬁde formation
with cellular proteins to maintain a low steady-state intracellular
concentration of GSSG.
A loss of GSH without cytotoxicity, such as that observed with
oxLDL, 27OH-C, or BSO treatment, can activate redox-sensitive
enzymes. Acid and neutral SMase are redox-regulated enzymes
[41–43] that hydrolyze sphingomyelin to ceramide and phospho-
choline. Activation of ASMase correlates with translocation of the
enzyme from intracellular stores to the extracellular leaﬂet of the
cell membrane [41]. ASMase generates transient ceramide accu-
mulation in acidic cellular compartments within minutes. There is
considerable evidence that ceramides induce lipid raft clustering
into unusually large raft domains in plasma membranes called
“ceramide-enriched membrane platforms” [44,45]. A thiol group
stabilizes the inactive conformation of ASMases forming hydrogen
bonds with adjacent electron donors. Deprotonation of the thiol
group and formation of an intermediate thioester bond mediates
the “cysteine switch” activation mechanism [46]. Here we have
conﬁrmed that ASMase showed greatest activation within 2 h of
oxLDL and lipid treatment. Moreover, using confocal microscopy
and sucrose density gradient centrifugation we showed that lipid
raft formation was also increased under these conditions. Even
though ASMase activity was still elevated at 16 h, BACE activation
or lipid raft assembly was not observed. This may be due to
internalization of lipid rafts and associated protein into endosomes
[47]. Activity of ASMase was inhibited by the tricyclic antidepres-
sant drug desipramine, which also acts as a direct ligand at the α
(2A) adrenergic receptor [48].
The formation of Aβ follows cleavage of APP ﬁrst by BACE1,
which allows further processing by γ-secretase to produce the
4-kDa Aβ peptide. Lipid raft formation has been previously
reported to promote the membrane association of APP, presenilin,
and BACE1 and to increase Aβ production. Here, oxLDL lipids, GSH
depletion, and 27OH-C treatment increased β-amyloid secretion
into the medium. OxLDL induced the largest increase in Aβ
secreted from SH-SY5Y cells. Although Aβ is usually degraded
after it is formed, the increase in secreted Aβ levels may be in part
a result of the cell's inability to degrade Aβ, e.g., through
proteasomal inhibition and failure of autophagy [49]. OxLDL is
known to impair proteasome activity, offering further explanation
for the failure to clear any increased concentrations of Aβ in the
presence of oxidized lipids [50].
Recent ﬁndings using in vitro systems have shown upregula-
tion of β-secretase activity and Aβ release after 27-OHC treatment
[23,38,51]. Aligned with our ﬁndings, Gamba et al. [38] found that
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BACE activity was prevented when cells were pretreated with
NAC. This suggests the involvement of the redox environment in
27-OHC-induced Aβ secretion [38]. A rare hereditary disease, spastic
paresis, is characterized by massive neurodegeneration associated
with high levels of 27OH-C, one of the major oxidized lipids found
in LDL, in plasma and cerebrospinal ﬂuid (CSF) [14]. Shafatti et al.
[13] demonstrated a modest accumulation of 27OH-C in brains of
patients with sporadic AD; a fourfold accumulation of 27OH-C
(7.871.8 ng 27OH-C/mg tissue compared with 1.870.8 ng 27OH-
C/mg tissue in control tissue from cortex) was observed in
different regions of the cortexes of patients carrying the Swedish
amyloid precursor protein (APPswe) 670/671 mutation, further
implicating oxidized lipids in the pathogenesis of AD. In addition
to the previous report of an increase in BACE1 gene expression and
Aβ formation after 27OH-C treatment in SH-SY5Y cells, our study
shows that GSH concentration-dependent lipid raft formation is a
key regulator of BACE1 activity and Aβ secretion.
The present ﬁndings support the importance of managing
cholesterol levels to minimize the potential for LDL-lipid modiﬁ-
cation by oxidation, or perhaps by glycation during diabetes.
Bayer-Carter and colleagues [52] showed that a high-saturated-
fat, high-sugar diet for a month, compared to a diet low in
saturated fats and simple sugars, caused signiﬁcant and opposing
changes in several CSF biomarkers, including dramatic changes in
Aβ42 in elderly subjects. According to the population attributable
risks estimates of Barnes and Yaffe, 2% of dementia cases world-
wide are due to diabetes, so that a 10% lower prevalence of
diabetes would lead to about 81,000 fewer cases of AD [53].
In summary, this study showed that nontoxic concentrations of
oxLDL lipids and 27OH-C decrease GSH/GSSG ratio and increase
extracellular Aβ secretion by SH-SY5Y cells through activation of
sphingomyelinase. This work offers an explanation for the associa-
tion between hypercholesterolemia, increased plasma levels of
oxLDL, Aβ accumulation, neuronal loss, and the onset of AD.
Reducing LDL oxidation in midlife could provide an important
therapeutic strategy for delaying AD onset and progression.
Importantly this work also suggests that sphingomyelinase offers
a novel target to mitigate the effects of oxLDL lipid stress.
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